Compound tracker
LSD.
A source-backed research page for trial rows and update notes connected to this compound or investigational product. The page is generated from the Notion tracker and should be read as a living research map, not a medical conclusion.
9 trial rows 2 update rows Latest checked: May 17, 2026 All trials Claim boundary
Trial registration, company topline, CNPV/rolling-review status, recruitment status, public-dashboard data, or review literature do not equal approval, label, reimbursement, access, safety, or efficacy. Related update rows are shown only when they include visible Last checked text and an explicit Claim boundary.
Backlinks
This page links out to registry/source records, the global trial tracker, the updates feed, and matching wiki dossiers when available.
Phase 1 / Phase 3
Phases tracked
Active not recruiting / Completed / Recruiting
Statuses seen
Trial rows
NCT06809595 Phase 3 Active not recruiting updated May 1, 2026
- Condition
- Generalized Anxiety Disorder
- Sponsor / institution
- Definium Therapeutics US, Inc.
- Start date
- Jan 29, 2025
Tracker note / source boundary
Last checked 2026-05-15 UTC. Claim boundary: registry/company tracker only; investigational DT120/MM120/lysergide tartrate is not approved and rows do not establish efficacy, safety, label, reimbursement, or access. ClinicalTrials.gov v2: ACTIVE_NOT_RECRUITING; estimated enrollment n=250; actual start 2025-01-29; arms placebo, 50µg MM120, 100µg MM120; primary outcome HAM-A total score change baseline to Week 12. Definium May 7/Apr. 22 releases say screening closed / sample-size re-estimation target 200 and topline expected late 3Q 2026; keep registry and company facts separated.
NCT06741228 Phase 3 Active not recruiting updated May 1, 2026
- Condition
- Generalized Anxiety Disorder
- Sponsor / institution
- Definium Therapeutics US, Inc.
- Start date
- Dec 11, 2024
Tracker note / source boundary
Last checked 2026-05-15 UTC. Claim boundary: registry/company tracker only; investigational DT120/MM120/lysergide tartrate is not approved and rows do not establish efficacy, safety, label, reimbursement, or access. ClinicalTrials.gov v2: ACTIVE_NOT_RECRUITING; actual enrollment n=214; actual start 2024-12-11; primary outcome HAM-A total score change baseline to Week 12; 100µg MM120 vs placebo. Definium May 7, 2026 Q1 release says enrollment complete and topline expected early 3Q 2026.
NCT06941844 Phase 3 Active not recruiting updated Mar 13, 2026
- Condition
- Major Depressive Disorder
- Sponsor / institution
- Definium Therapeutics US, Inc.
- Start date
- Apr 14, 2025
Tracker note / source boundary
Last checked 2026-05-15 UTC. Claim boundary: registry/company tracker only; investigational DT120/MM120/lysergide tartrate is not approved and rows do not establish efficacy, safety, label, reimbursement, or access. ClinicalTrials.gov v2: ACTIVE_NOT_RECRUITING; actual enrollment n=149; actual start 2025-04-14; primary outcome MADRS total score change baseline to Week 6; 100µg MM120 vs placebo. Definium May 7, 2026 Q1 release says enrollment complete and topline expected late 2Q 2026.
NCT07061886 Phase 1 Recruiting updated Jul 11, 2025
- Condition
- LSD
- Sponsor / institution
- University of Chicago
- Start date
- Jun 26, 2025
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: RECRUITING | Exact phase: Early Phase 1 | Lead sponsor: University of Chicago | Conditions: LSD
NCT04227756 Phase 1 Completed updated Jan 24, 2024
- Condition
- Healthy
- Sponsor / institution
- University Hospital, Basel, Switzerland
- Start date
- May 19, 2020
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 1 | Lead sponsor: University Hospital, Basel, Switzerland | Conditions: Healthy
NCT04516902 Phase 1 Completed updated Aug 23, 2022
- Condition
- Healthy
- Sponsor / institution
- University Hospital, Basel, Switzerland
- Start date
- Jan 1, 2021
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 1 | Lead sponsor: University Hospital, Basel, Switzerland | Conditions: Healthy
NCT04558294 Phase 1 Completed updated Oct 21, 2021
- Condition
- Healthy
- Sponsor / institution
- University Hospital, Basel, Switzerland
- Start date
- Oct 16, 2020
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 1 | Lead sponsor: University Hospital, Basel, Switzerland | Conditions: Healthy
NCT01878942 Phase 1 Completed updated Jan 21, 2016
- Condition
- Healthy
- Sponsor / institution
- University Hospital, Basel, Switzerland
- Start date
- —
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Early Phase 1 | Lead sponsor: University Hospital, Basel, Switzerland | Conditions: Healthy
NCT02308969 Phase 1 Completed updated Sep 25, 2015
- Condition
- Healthy
- Sponsor / institution
- University Hospital, Basel, Switzerland
- Start date
- —
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Early Phase 1 | Lead sponsor: University Hospital, Basel, Switzerland | Conditions: Healthy
Related updates
May 17, 2026 Last checked 2026-05-17 07:00 UTC Trial Update Company
Claim boundary.Definium Ascend remains company-release tracked until registry/results artifacts appear; no approval/access/efficacy/safety upgrade.
Last checked: 2026-05-17 07:00 UTC. Targeted ClinicalTrials.gov searches for Ascend DT120, Definium Ascend, lysergide tartrate MDD Ascend, and DT120 MDD still did not find an Ascend NCT; DT120 MDD search returned older/non-Ascend NCT05407064. Claim boundary: Definium Ascend remains company-release tracked until registry/results artifacts appear; no approval/access/efficacy/safety upgrade.
Source/tracker note
Targeted ClinicalTrials.gov output: Ascend DT120 / Definium Ascend / lysergide tartrate major depressive disorder Ascend = no results; DT120 major depressive disorder returned NCT05407064, not Ascend.
May 15, 2026 Last checked 2026-05-15 UTC Publication Research
Claim boundary.nonmedical-use epidemiology and public-health context only; self-report survey correlates are not clinical efficacy evidence, therapeutic safety evidence, approval/access evidence, or a basis for causal claims about LSD.
PubMed PMID 42131859 reports an analysis of 2015-2019 NSDUH data among U.S. adults who first used LSD at least five years earlier; estimated 4.2% used LSD in the past year, with past-year use declining as time since initiation increased and correlates including perceived lower risk/higher availability and other substance-use variables.
Source/tracker note
Last checked 2026-05-15 UTC. Claim boundary: nonmedical-use epidemiology and public-health context only; self-report survey correlates are not clinical efficacy evidence, therapeutic safety evidence, approval/access evidence, or a basis for causal claims about LSD.
Conditions touched
Generalized Anxiety DisorderHealthyLSDMajor Depressive Disorder